Two presentations at the 25th Annual San Antonio Breast Cancer Symposium on Dec. 11 suggest new treatment options in advanced breast cancer refractory to conventional chemotherapy. A double-blind crossover trial showed that anastrozole (ARI) should be given as first-line adjuvant therapy with tamoxifen (TAM) used after first progression for women with advanced breast cancer. Another trial found that fulvestrant is efficacious even after failure of both tamoxifen and aromatase inhibitors.
“In patients with endocrine-responsive disease and indication for second-line endocrine therapy, ARI showed longer time-to-progression than TAM when given as first-line therapy,” write B. Thuerlimann and colleagues from Berne, Switzerland. “After crossover, both ARI and TAM have similar activity. These results are supportive of the recommendation to give ARI as first-line treatment for advanced breast cancer in postmenopausal women with estrogen and/or progesterone receptor-positive disease.”
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!